AMERISE BIOSCIENCES LIMITED is a Industrial Products company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 10 | 0 | 0 | 0 | 0 |
| EBITDA (ex other income) | 1 | (0) | (0) | 0 | 0 |
| margin % | 5.7 | — | — | 4.0 | 8.1 |
| Owners' profit | 1 | (0) | (0) | 0 | 0 |
| EPS, as reported (₹) | 0.08 | (0.02) | (0.02) | 0.00 | 0.00 |
| ROE % · ROCE % | 9.7 · 9.6 | (2.2) · (2.1) | (2.7) · (2.7) | 0.1 · 0.1 | 0.3 · 0.4 |
| Debt / equity (x) | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 0 | (0) | (0) | 3 | (1) |
| Capex | 0 | 0 | 0 | 0 | 0 |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | (0) | (0) | 0 | (0) | (0) | 0 | 0 | (0) |
| Net profit | (0) | (0) | 0 | (0) | (0) | 0 | 0 | (0) |
| EPS (₹) | (0.01) | 0.00 | 0.02 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUPREME INDUSTRIES LTD | 42,745 | 41.2 | 6.93 | 26.3 | 15.5 | 17.9 | 12.0 | 15.0 |
| ASTRAL LIMITED | 37,967 | 65.9 | 9.36 | 34.3 | 13.2 | 16.9 | 15.6 | 15.5 |
| GARWARE HI-TECH FILMS LTD | 16,077 | 41.5 | 6.05 | 31.9 | 12.7 | 16.4 | 16.5 | 30.3 |
| FINOLEX INDUSTRIES LTD | 9,504 | 15.4 | 1.53 | 11.1 | 9.6 | 11.8 | 3.5 | 20.6 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 1 Sept 2026 · Annual Report FY2025-26 and 41st AGM notice submitted to BSE | board shareholder meetings | medium | — | — |
| 1 Sept 2026 · Book closure from Sep 17 to Sep 24 2026 for AGM | corporate actions | low | — | — |
| 1 Sept 2026 · 41st AGM notice on Sept 24; seeks approval for director appointment | board shareholder meetings | low | — | — |
| 18 Aug 2026 · Snehjeev Ventures and PACs cross 11% stake in Amerise Biosciences via open market | ownership changes | high | — | — |
| 3 Aug 2026 · Q1 FY27 loss widens to Rs 8.14L; revenue drops to zero | results | high | — | — |
| 3 Aug 2026 · Q1 FY27 loss at Amerise Biosciences amid zero revenue | results | high | — | — |
| 3 Aug 2026 · Q1 FY27 results: Revenue nil, loss widens to Rs 8.14 lakh | results | medium | — | — |
| 29 Jul 2026 · Snehjeev Ventures crosses 9 percent in Amerise Biosciences via open market | ownership changes | medium | — | — |
| 22 Jul 2026 · Snehjeev Ventures crosses 9% stake in Amerise Biosciences via open market | ownership changes | high | — | — |
| 21 Jul 2026 · Board meeting on 3 Aug 2026 to consider Q1 FY27 results | results | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| TIME TECHNOPLAST LTD. | 8,934 | 17.6 | 2.14 | 10.0 | 11.4 | 14.0 | 15.2 | 13.3 |
| KINGFA SCI & TEC IND LTD. | 8,422 | 37.3 | 6.02 | — | 13.2 | 17.7 | — | 16.9 |
| PRINCE PIPES FITTINGS LTD | 2,950 | 28.9 | 1.79 | — | 4.5 | 5.6 | — | 13.3 |
| APOLLO PIPES LIMITED | 2,444 | — | 2.74 | 32.3 | 0.5 | 1.0 | — | 1.8 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 27.7 | 15.2 | 41 of 54 | 25% |
| P/B | 1.0 | 1.8 | 9 of 43 | 81% |
| ROCE | 0.4 | 7.1 | 46 of 57 | 20% |
| ROE | 0.3 | 7.6 | 38 of 48 | 21% |
| Debt / Equity | 0.0 | 0.1 | 4 of 48 | 77% |
| Revenue growth | (100.0) | 10.6 | 47 of 49 | 0% |
| Profit growth | (906.2) | 20.7 | 46 of 47 | 2% |
| Market cap | 5 | 130 | 54 of 56 | 4% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
